poly- 1- 6- glucopyranosyl- 1- 3- glucopyranose glucan

based on carbohydrate polymers derived from yeast; used for reducing the severity and incidence of infections in immune-compromised patients, patients undergoing surgical procedures, and in patients with nosocomial infections

Also Known As:

Networked: 16 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ostroff, Gary: 2 articles (03/2003 - 08/2002)
2.	Ayala, Alfred: 1 article (12/2011)
3.	Flores, Estefany: 1 article (12/2011)
4.	Gregory, Stephen: 1 article (12/2011)
5.	Newsome, Courtni T: 1 article (12/2011)
6.	Reichner, Jonathan S: 1 article (12/2011)
7.	Brousseau, Pauline: 1 article (03/2003)
8.	Kournikakis, Bill: 1 article (03/2003)
9.	Mandeville, Rosemonde: 1 article (03/2003)
10.	Genco, Caroline: 1 article (08/2002)

Related Diseases

1.	Infections 11/01/1994 - "The safety and efficacy of PGG-glucan in surgical patients at high risk for postoperative infection who underwent major thoracic or abdominal surgery were determined. " 03/01/1998 - "Furthermore, a single dose of PGG glucan given 24 h following bacterial inoculation was found to be effective in preventing infection. " 11/01/1994 - "PGG-glucan was generally safe and well tolerated, may decrease postoperative infection rates, and warrants further investigation in a planned phase III trial." 12/01/2011 - "Since gender-dependent differences in host immune response to infection have been reported, male and female mice were prospectively stratified for PGG glucan treatment. " 09/01/1999 - "Perioperative administration of PGG-glucan reduced serious postoperative infections or death by 39% after high-risk noncolorectal operations."
2.	Sepsis (Septicemia) 12/01/2011 - "Together, the translational potential of these findings is the indicated use of PGG glucan given locally, rather than intravenously, for improved source control during the management of sepsis. " 11/01/1994 - "The efficacy of PGG-glucan pretreatment in prevention of sepsis has been demonstrated in rodent models for gram-negative and gram-positive bacterial and yeast infections. " 10/25/1996 - "In the present studies, we examined the ability of PGG glucan to act in concert with antibiotics to decrease mortality in a rat model of intraabdominal sepsis using antibiotic-resistant bacteria as infectious inocula. " 07/01/1998 - "Two immunomodulating polysaccharides, poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG)-glucan and Bacteroides fragilis polysaccharide A (PS A), were evaluated for the prevention of mortality and abscess formation associated with experimental intraabdominal sepsis. "
3.	Peritonitis 04/01/1992 - "Mice challenged with Escherichia coli or Staphylococcus aureus were protected against lethal peritonitis by the intravenous administration of 10 micrograms of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose (PGG) glucan per animal 4 to 6 h prior to bacterial challenge. " 06/01/1996 - "These results suggest that the protective effect exhibited by PGG glucan in the rat peritonitis model is mediated, at least in part, by prostaglandins." 06/01/1996 - "Administration of a purified prostaglandin extract from the sera of PGG glucan-treated animals protected against mortality in the peritonitis model. " 06/01/1996 - "Previous studies have established the efficacy of soluble polymers of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG) glucan, a biological-response modifier, in protecting against mortality associated with experimentally induced peritonitis in a rat model. " 09/01/1999 - "PGG-glucan (Betafectin; Alpha Beta Technology Inc, Worcester, Mass), derived from yeast cell walls, promotes phagocytosis and intracellular killing of bacterial pathogens by leukocytes, prevents infection in an animal model of wound infection, and acts synergistically with antibiotics to reduce mortality in rat peritonitis. "
4.	Bone Resorption 01/01/1995 - "Finally, PGG glucan had no effect on either PTH- or IL-1-stimulated bone resorption in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/1995 - "In the present studies, the effect of PGG glucan on infection-stimulated alveolar bone resorption was tested in an in vivo model. " 01/01/1995 - "PGG glucan-treated animals had significantly less infection-stimulated periapical bone resorption than control animals, as determined radiographically (-48.0%; p < 0.001) and by histomorphometry (-40.8% and -42.4% for first and second molars, respectively; p < 0.001). " 01/01/1995 - "Reduction of infection-stimulated periapical bone resorption by the biological response modifier PGG glucan."
5.	Wound Infection (Wound Infections) 09/01/1998 - "PGG-glucan and cefazolin are synergistic in their ability to prevent staphylococcal wound infection." 09/01/1999 - "PGG-glucan (Betafectin; Alpha Beta Technology Inc, Worcester, Mass), derived from yeast cell walls, promotes phagocytosis and intracellular killing of bacterial pathogens by leukocytes, prevents infection in an animal model of wound infection, and acts synergistically with antibiotics to reduce mortality in rat peritonitis. "

Related Drugs and Biologics

1.	Immunologic Factors (Immunomodulators)
2.	Polymers
3.	Anti-Bacterial Agents (Antibiotics)
4.	Glucans
5.	Polysaccharides (Glycans)
6.	poly- 1- 6- glucopyranosyl- 1- 3- glucopyranose glucan
7.	beta-Glucans
8.	Interleukin-11 (Interleukin 11)
9.	Thromboplastin (Tissue Factor)
10.	Prostaglandins

Related Therapies and Procedures

1.	Intravenous Administration
2.	Antibiotic Prophylaxis
3.	Punctures
4.	Ligation
5.	Length of Stay